← ANALYST RATINGS · TIPRANKS

Praxis Precision Medicines (PRAX): analyst forecast and price target

$242 −2.61% close 16.10.26 · market cap $6.9B · Healthcare · Biotechnology IWM 0.21%
Price targets and ratings of

Analyst consensus

Strong Buy

16 Buy1 Hold0 Sell

Ratings of 17 analysts in the last 3 months

12-month forecast

$702+190.4% upside

Based on 17 price targets given in the last 3 months, the average target is $702, the highest $1,201, the lowest $362. The average is +190.4% from the last price of $242.

$500$1,000Jan 26AprJulOctJan 27AprJulOctHigh$1,201Average$702Low$362
Highest target $1,201 Average target $702 Lowest target $362
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% J.P. Morgan $700 Buy +189.5% Initiated 15.10.26on TipRanks 16:35 −1.5%
Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% H.C. Wainwright $1,201 Buy +396.8% Reiterated 15.10.26on TipRanks 07:15 +3.6%next day −1.5%
Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% Truist Financial $706 Buy +192.0% Initiated 14.10.26on TipRanks 19:50 +3.6%next day −1.5%
Kambiz Yazdi★★★★★★★★★★#1181 · hits 67% · avg +24.8% BTIG $810 → $826+2.0% Buy +241.7% Assigned 06.10.26on TipRanks 06:50 −1.8%next day −0.5% · 5 days −13.0%
Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% H.C. Wainwright $1,201 Buy +396.8% Reiterated 05.10.26on TipRanks 13:25 −4.7%next day −1.8% · 5 days −11.8%
Justin Walsh★★★★★★★★★★#640 · hits 39% · avg +20.6% JonesTrading $441 → $534+21.1% Buy +120.9% Reiterated 01.10.26on TipRanks 16:35 +2.3%next day −4.7% · 5 days −13.2%
Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% H.C. Wainwright $1,201 Buy +396.8% Reiterated 24.09.26on TipRanks 06:25 0.0%next day −0.9% · 5 days +2.2%
Ami Fadia★★★★★★★★★★#73 · hits 59% · avg +36.1% Needham $582 Buy +140.7% Reiterated 24.09.26on TipRanks 05:55 0.0%next day −0.9% · 5 days +2.2%
Kevin Strang★★★★★★★★★★#10513 · hits 33% · avg −19.6% Goldman Sachs $470 → $575+22.3% Buy +137.8% Assigned 21.08.26on TipRanks Aug 20 07:30 −4.8%next day +2.7% · 5 days −0.2%
Jay Olson★★★★★★★★★★#301 · hits 48% · avg +24.9% Oppenheimer $650 Buy +168.9% Reiterated 17.08.26on TipRanks Aug 18 05:55 +3.1%next day −1.1% · 5 days −1.0%
Tiago Fauth★★★★★★★★★★#1228 · hits 49% · avg +13.1% Raymond James $765 → $945+23.5% Buy +290.9% Reiterated 17.08.26on TipRanks 09:25 +3.1%next day −1.1% · 5 days −1.0%
Francois Brisebois★★★★★★★★★★#2595 · hits 43% · avg +5.9% LifeSci Capital $754 Buy +211.9% Assigned 08.08.26on TipRanks Aug 6 14:10 +16.1%next day −3.1% · 5 days −1.7%
Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% Piper Sandler $1,200 Buy +396.4% Reiterated 07.08.26on TipRanks 11:27 −3.1%next day +1.7% · 5 days +1.3%
Justin Walsh★★★★★★★★★★#640 · hits 39% · avg +20.6% JonesTrading $441 Buy +82.4% Reiterated 07.08.26on TipRanks 08:35 −3.1%next day +1.7% · 5 days +1.3%
Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% Robert W. Baird $400 → $514+28.5% Buy +112.6% Reiterated 07.08.26on TipRanks 08:10 −3.1%next day +1.7% · 5 days +1.3%
Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% Truist Financial $616 Buy +154.8% Reiterated 07.08.26on TipRanks 08:01 −3.1%next day +1.7% · 5 days +1.3%
Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% Wells Fargo $323 → $362+12.1% Hold +49.7% Reiterated 07.08.26on TipRanks 07:06 −3.1%next day +1.7% · 5 days +1.3%
Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% Guggenheim $800 Buy +230.9% Reiterated 06.08.26on TipRanks Aug 7 08:01 +16.1%next day −3.1% · 5 days −1.7%
Leonid Timashev★★★★★★★★★★#279 · hits 60% · avg +24.5% RBC Capital $449 → $462+2.9% Buy +91.1% Assigned 06.08.26on TipRanks Aug 7 07:06 +16.1%next day −3.1% · 5 days −1.7%
Ritu Baral★★★★★★★★★★#49 · hits 58% · avg +46.9% TD Cowen $510 Buy +111.0% Reiterated 06.08.26on TipRanks Aug 7 04:00 +16.1%next day −3.1% · 5 days −1.7%
Andrew Tsai★★★★★★★★★★#339 · hits 63% · avg +29.9% Jefferies $550 Buy +127.5% Reiterated 30.06.26on TipRanks 08:45 −5.3%next day −4.4% · 5 days −0.4%
Kambiz Yazdi★★★★★★★★★★#1181 · hits 67% · avg +24.8% BTIG $810 Buy +235.0% Reiterated 29.06.26on TipRanks Jun 30 06:10 +5.3%next day −5.3% · 5 days −8.5%
Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% Wedbush $166 → $162−2.4% Sell −33.0% Reiterated 02.06.26on TipRanks 07:55 −23.1%next day +8.8% · 5 days 0.0%
David Hoang★★★★★★★★★★#485 · hits 67% · avg +34.8% Deutsche Bank $420 → $374−11.0% Buy +54.7% Reiterated 02.06.26on TipRanks 04:35 −23.1%next day +8.8% · 5 days 0.0%
Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% Wolfe Research $500 Buy +106.8% Reiterated 06.04.26on TipRanks Apr 7 08:15 −0.6%next day −1.1% · 5 days −1.9%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Praxis Precision Medicines

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Yatin Suneja★★★★★★★★★★Guggenheim · #120
Hits 57%244 of 428 Average return +33.0%
1 year Joon Lee★★★★★★★★★★Truist Financial · #73
Hits 58%278 of 483 Average return +36.3%
2 years Joon Lee★★★★★★★★★★Truist Financial · #73
Hits 58%278 of 483 Average return +36.3%

Most profitable

3 months Yasmeen Rahimi★★★★★★★★★★Piper Sandler · #160
Hits 51%247 of 488 Average return +36.0%
1 year Joon Lee★★★★★★★★★★Truist Financial · #73
Hits 58%278 of 483 Average return +36.3%
2 years Yasmeen Rahimi★★★★★★★★★★Piper Sandler · #160
Hits 51%247 of 488 Average return +36.0%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $693 at a price of $291 (+138.0%); now: $702 at $242 (+190.4%).

$400$600Sep 15Oct 1Oct 15Top analysts$742Average target$702Price$242

PriceAverage targetTop analysts’ target

Recommendation trend

02040602391Oct 252514Nov32231Dec27242Jan 26302123Feb23822Mar28841Apr28621May45942Jun35822Jul331131Aug1381Sep1751Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy284535331317
Buy6981185
Hold242311
Sell122100

Earnings and sales forecast

Next report: 11.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $-3.54 (from $-4.23 to $-2.74). Last quarter: $-2.87.

Sales

Next quarter’s sales estimate — $0M (from $0M to $0M). Last quarter: $0M.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About Praxis Precision Medicines

Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.

Data from the stock’s TipRanks forecast page, read 38 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗